Mergers & Acquisitions ·
Sanofi announced a strategic partnership with Cheplapharm to divest a selection of 20 mature medicines and three…
SNYSanofi
Sanofi announced a strategic partnership with Cheplapharm to divest a selection of 20 mature medicines and three manufacturing sites (in Hungary, Singapore, and France) in exchange for a 26.4% equity stake in Cheplapharm. The transaction includes the flagship product Lovenox/Clexane and is expected to close by the third quarter of 2027, subject to regulatory approvals and customary conditions. Sanofi stated the deal would not impact its 2026 financial guidance. This strategic move allows Sanofi to simplify its mature portfolio while Cheplapharm expands its capabilities in well-established medicines.